ImmuCell (ICCC) President and CEO Olivier Buys $76K of Stock

On June 18, 2026, ImmuCell Corporation's President and CEO, Paul Te Boekhorst, purchased 8,000 shares of the company at $9.50 each. This transaction amounted to a total investment of $76,000. The purchase was not part of a pre-arranged trading plan.

Insider Buying and Selling at ImmuCell Corporation

Paul Te Boekhorst, the President and CEO of ImmuCell Corporation, bought 8,000 shares on June 18, 2026, at an average price of $9.50, totaling $76,000. This move was not conducted under a Rule 10b5-1 trading plan. Other insiders, including David Scott Tomsche and Paul Wainman, also made purchases earlier in April, acquiring 11,933 shares each.

Other Institutional Activity in ImmuCell Corporation

Vanguard Capital Management opened a new position in ImmuCell Corporation, acquiring 260,327 shares valued at about $1.65 million. Morgan Stanley increased its holdings by 97,000 shares, bringing its total to 221,716 shares worth approximately $1.40 million, reflecting a 77.8% increase. Renaissance Technologies added 1,100 shares, resulting in 151,789 shares valued at $960,824, marking a 0.7% increase. In contrast, Geode Capital Management reduced its holdings by 6,492 shares, leaving it with 65,765 shares worth $416,393, a 9.0% decrease.

ImmuCell Corporation Stock Down 2.0%

Shares of NasdaqCM:ICCC traded near $9.49 on Tuesday. ImmuCell Corporation has a market capitalization of approximately $88.2 million. The company's forward P/E ratio is not meaningful as it isn't currently profitable, with a beta of 0.98. The stock's 52-week range is between $4.52 and $10.75, with a 50-day moving average of $8.93 and a 200-day moving average of $6.84. ImmuCell maintains a strong liquidity position with a current ratio of 4.82 and a quick ratio of 2.43, though it carries a debt-to-equity ratio of 43.86.

Recent Earnings

ImmuCell Corporation reported revenue of $29.93 million, showing a growth of 28.4%. Despite this growth, the company posted a net margin of -1.82% and a return on equity of -1.88%, indicating a lack of profitability. The next earnings report is expected on August 13, 2026.

About ImmuCell Corporation

ImmuCell Corporation, headquartered in Portland, Maine, is a biotechnology company focused on animal health. It develops, manufactures, and markets products to enhance the health and productivity of dairy and beef cattle. The company operates in two main segments: Scours and Mastitis. Key products include First Defense, a preventive treatment for calves, and Re-Tain, a treatment for mastitis in dairy cows. ImmuCell was founded in 1982 and employs 73 people.

Bottom Line

ImmuCell's CEO Paul Te Boekhorst's recent stock purchase reflects his confidence in the company's prospects. Investors often track insider transactions like this for insights into management's outlook. As a reminder, insider buying and selling disclosures are historical and do not necessarily indicate future stock performance.